Citius Pharmaceuticals, Inc. cash flow statement CTXR

Annual Quarterly

In fiscal 2025, which ended Sep 30, 2025, Citius Pharmaceuticals, Inc. used $26.6 million of cash from operations, up 5.8% from the year before.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Sep 30, 2025	FY 2024 Sep 30, 2024	FY 2023 Sep 30, 2023	FY 2022 Sep 30, 2022	FY 2021 Sep 30, 2021	FY 2020 Sep 30, 2020	FY 2019 Sep 30, 2019	FY 2018 Sep 30, 2018	FY 2017 Sep 30, 2017	FY 2016 Sep 30, 2016
Operating
Depreciation and amortization	—	—	0 -46.3%	0 -8.7%	0 +95.9%	0 +76.8%	0 -5.5%	0 -49.1%	0 -33.4%	0 +96.0%	0
Stock-based compensation	15 +39.5%	11 -8.5%	12 +78.9%	7 +69.4%	4 +168.5%	1 +81.1%	1 +12.2%	1 -8.2%	1 -21.0%	1 +34.8%	1 +50.6%
Operating cash flow	-35 -69.4%	-27 +5.8%	-28 +3.0%	-29 -2.5%	-28 -17.0%	-24 -43.2%	-17 -36.1%	-12 -9.9%	-11 -42.0%	-8 -35.1%	-6 -147.4%
Investing
Capital expenditures	—	—	—	—	—	0 +278.9%	0 -13.9%	—	—	0	—
Investing cash flow	—	-6 -15.0%	-5	—	—	-40 -2184877.5%	-0 +13.9%	—	—	-0 -100.8%	0
Financing
Financing cash flow	59 +325.3%	33 +234.0%	10 -27.9%	14 -88.5%	—	120 +426.1%	23 +105.4%	11 -35.6%	17 +58.9%	11 +106.8%	5 +248.7%
Change in cash
Free cash flow	—	—	—	—	—	-24 -43.3%	-17 -36.1%	—	—	-8	—
Per share
Dividend per share	—	—	—	—	—	—	—	—	—	—	0.60
Ratios
Free cash flow margin	—	—	—	—	—	-26,952.61%	-18,813.88%	—	—	—	—
Capital expenditures to revenue	—	—	—	—	—	7.71%	2.03%	—	—	—	—
Stock-based compensation to revenue	—	—	—	—	4,339.95%	1,616.64%	892.51%	795.54%	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: CTXR (Nasdaq)
Fiscal year ends: September 30
Incorporated in: NV
Headquarters: Cranford, NJ
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1506251
Former names: Trail One, Inc. (until Sep 18, 2014); TrailOne, Inc. (until Jan 21, 2011)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.